Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Semaglutide

BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity

Novo Nordisk · Phase 3 · Not yet recruiting · Enrollment 352

NCT07622810

ArmPopulationDoseWeeksEstimandWeight change
Group A: Bofanglutida (GZR18),Obesity or overweightn/r36n/rn/r
Group B: SemaglutideObesity or overweightn/r36n/rn/r